CytRx Corp (NASDAQ:CYTR)

Like Insmed, Ardea, and countless others before CytRx has reinvented itself through acquisitions. In 5/11 the company sold the remnants of their small molecule chaperone program for "up to" 120M in milestones from Orphazyme. The upfront payment was apparently so small the company was embarrassed to mention it.

The pipeline now consists entirely of compounds brought in by the acquisition of privately-held Innovive Pharmaceuticals in 2008. Even though the acquisition price was only 21M, I couldn't find the ding in CytRx's financial statements and they didn't appear to issue any new shares. Also, with the mileage CytRx has dug out of Innovive's pipeline I'm a little surprised Innovive didn't just IPO themselves. Shenanigans?

Regardless, CytRx seems to have quite a lot going on at the present time for a sub 100M cap. Three oncology candidates are in clinical trials which appear to be progressing according to plan. Kinase inhibitor bafetinib, currently in two proof-of-concept phase II trials, is particularly interesting. The share price hasn't been this low since last summer doldrums. Although I'm skeptical about the long-term prospects of this cheaply acquired pipeline, I do see a high potential for a significant upward move within the next few months.

Current clinicals , existing documented cases under compassionary use. Shall we be honest all Bio stocks come with risk but IMO this team is close...call it Speculation but IMO well timed...phase 1 target 2.35. Disclosure: You should always assume anytime someone talks about a stock that they are long or short...LONG here.

Lots of cash; great and experienced mgt; great pipeline

quick grab on fda fears

Good platform of trials, take over target.

I think he stock will outperform because the company has three research platforms and a lot of new products that will come to market next year

A buy at $3.30 or less...

really new technology with a nobel prize winner on the board of directors

Bought today.

CYTR pipeline looks good and the recent spin off of RXi (RNA) that they will own 49% is in a very hot sector of biopharm.

This is a company with RNAi tech and the company will have several important announcements within several months.

Nice accumulation and uptrend

This stock may be near-term overpriced, but I believe its technology will lead to outsized returns over the long run, with intermittent large spikes in the stock price (upward as well as downward, but overall up). I am holding a small position from several weeks ago, from about 4.95. I will add to my position eventually.

CYTR has one of the top experts in the world on RNAI technology. He won the 2006 Nobel Prize in recognition of the potential for RNAI to create therapies for CANCER and other diseases that make them things of the past. CYTR's drug Arimolclomol has been given fast track status by the FDA. CYTR is using its proven delivery method which gives it a signigicant advantage in the market place.

This stock is at its begining and will easily be a ten bagger.

Cutting edge research, excellent staff.

Cytr has all the makings of a very good approach to medicine...just like the discovery of the vaccine...which was developed thru good overservations..like the earlier milkmaids who developed boils as result to exposures to diseased animals but did not develope the worse disease like small pox, etc. Careful and persistent researches and more advanced technology is now making it possible to go fast forward with this new medical approach to ever increasing spread of old and modern diseases. The beauty of this technique is that the developed interferones (RNAi) select only the malignant cells without harming the surrounding healthy cells. Knowledge coupled with advanced technology definitely will bring success to this new medical approach!

RNAi technology is on the innovative front edge. SIrna's purchase by Merck lends them credibility in a burgeoning space.

This company has money in the bank out the wazoo and 0 debt. How can anyone not see that there has to be growth there?

big opps